V50G (p.Val50Gly) variant of TTR (Transthyretin)

V50G (p.Val50Gly) in TTR (Transthyretin) is a missense change. Clinical records from ClinVar, EBI, and UniProt describe it as pathogenic in the context of Amyloidosis, hereditary systemic 1. The available variant effect predictions contribute to a CATVariant prioritization score of 0.69 / 1. The record also includes published literature and structural context.

V50G (p.Val50Gly) variant details